288 related articles for article (PubMed ID: 29338536)
1. P2Y
Kupka D; Sibbing D
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):303-315. PubMed ID: 29338536
[TBL] [Abstract][Full Text] [Related]
2. P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes.
Höchtl T; Huber K
Hamostaseologie; 2014; 34(1):20-8. PubMed ID: 24220294
[TBL] [Abstract][Full Text] [Related]
3. Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Rollini F; Franchi F; Angiolillo DJ
Nat Rev Cardiol; 2016 Jan; 13(1):11-27. PubMed ID: 26283269
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
5. Switching P2Y
Rollini F; Franchi F; Angiolillo DJ
Interv Cardiol Clin; 2017 Jan; 6(1):67-89. PubMed ID: 27886824
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
Shah R; Rashid A; Hwang I; Fan TM; Khouzam RN; Reed GL
Am J Cardiol; 2017 Jun; 119(11):1723-1728. PubMed ID: 28385176
[TBL] [Abstract][Full Text] [Related]
9. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
10. [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].
Olivier CB; Diehl P; Bode C; Moser M
Herz; 2014 Nov; 39(7):808-13. PubMed ID: 25359405
[TBL] [Abstract][Full Text] [Related]
11. De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review.
Han YL
Chin Med J (Engl); 2019 Jan; 132(2):197-210. PubMed ID: 30614864
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors.
Thomas MR; Storey RF
Vascul Pharmacol; 2016 Sep; 84():25-7. PubMed ID: 27275527
[TBL] [Abstract][Full Text] [Related]
13. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
Tan GM; Lam YY; Yan BP
Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
[TBL] [Abstract][Full Text] [Related]
14. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Parker WA; Storey RF
Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
Monitillo F; Iacoviello M; Caldarola P; Valle R; Chiatto M; Aspromonte N
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):977-93. PubMed ID: 25882759
[TBL] [Abstract][Full Text] [Related]
16. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
17. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
Collet JP; O'Connor S
Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
[TBL] [Abstract][Full Text] [Related]
18. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH; Phan YL; Spinler SA
Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
[TBL] [Abstract][Full Text] [Related]
19. [Clinical pharmacology of current antiplatelet drugs].
Trenk D; Nührenberg T; Stratz C; Valina CM; Hochholzer W
Herz; 2014 Nov; 39(7):790-7. PubMed ID: 25267101
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Serebruany VL; Dinicolantonio JJ; Can MM; Pershukov IV; Kuliczkowski W
Cardiology; 2013; 126(1):35-40. PubMed ID: 23860246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
